NeurogesX (NGSX) Gets FDA Acceptance for End-of-Phase 2 Meeting for NGX-1998

NeurogesX, Inc. (Nasdaq: NGSX), announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's request for an End-of-Phase 2 meeting to discuss the continued clinical investigation of NGX-1998 as a treatment for certain neuropathic pain conditions including, specifically, the Company's plans for entering NGX-1998 into Phase 3 development. The Company anticipates that the End-of-Phase 2 meeting will occur in the third quarter of 2012.

NGX-1998, NeurogesX' most advanced product candidate, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. The Company believes that the clinical data obtained to date should support moving to a Phase 3 clinical development program, which it believes can be initiated by the end of 2012.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Nu Skin EVP of global sales takes medical leave
• Home Depot expands executive roles, grants $500K in restricted stock